Ann: US FDA Grants Orphan Drug Designation to PTX-100 for PTCL, page-44

First 44 Last

Share
Profile

Follow
bobadah

10,458 Posts.

1157

15/07/22

16:00

Post #: 62557636
Share

Originally posted by Scooty ↑

Well bob I am on both mate, admittedly I have more exposure to IMU but I actually averaged up (bought more but at a higher SP than my current holding at the time) on my PTX shares when the announcement on 8th June came out about Cellpryme-M CAR-T which was clinic ready, adaptable and effectively able to "bolt on" as a superior cell product for CAR-T therapy. That announcement suggested to me that PTX were far closer (opinion only) to monetising their product than IMU (who are very good at what they do but look to licence/sell product after Phase 2 results). That is a big deal to me as a long term holder of MSB and watching the swings and roundabouts of owning bio's still trying to get their products on shelves in direct competition with BP and the regulatory world of the FDA.

With the tax loss selling through June I bought more as the SP softened and glad I did. Today's announcement confirmed my belief that PTX is on a pathway to monetising their products ahead of a lot of others. I certainly wouldnt sell my IMU to buy PTX, but I wont be selling any PTX either as I think head to head it will increase in value more in the next 6-12 months than my other little bio-darlings.

Just my opinion, but don't be turned off by the traders selling out before lunch, they're probably six beers into celebrating their profits by now!!!

Expand

I am also in both with IMU over 50% greater than PTX but I intend to keep them both a while yet. I do trade a bit with my IMU's but not much with the PTX.

PTX Price at posting: 18.0¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

What's causing the cost-of-living crisis, and how to navigate it

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon